Table 3.

Data of study subjects separated in treatment response groups.

	GR (n = 19)	PR (n = 16)	P	noRx (n = 8)	P (versus GR, PR)
Baseline characteristics
Female/male (n)	12/7	8/8	NS∗	5/3
Age at diagnosis (years)	31.42 ± 10.25	32.88 ± 10.82	0.68	38.38 ± 5.09	0.24, 0.36
Disease duration (years)	1.28 ± 2.36	2.31 ± 2.97	0.21	4.27 ± 5.18	0.18, 0.47
Pre-IFNβ ARR	1.46 ± 1.08	1.61 ± 0.52	0.45	0.54 ± 0.26	0.006, 0.003
T2 lesions	9.68 ± 6.17	12.31 ± 5.12	0.18	8.87 ± 4.08	0.73, 0.11
T1 Gd+ lesions	2.73 ± 2.30	2.31 ± 2.05	0.65	0.50 ± 0.53	0.01, 0.05
IgG index	1.11 ± 0.54	1.02 ± 0.76	0.39	0.85 ± 0.52	0.13, 0.31
CSF cells (per μL)	11.16 ± 8.65	10.81 ± 8.16	0.90	4.12 ± 5.79	0.05, 0.01
EDSS acute	2.74 ± 0.93	3.15 ± 0.89	0.27	1.81 ± 0.37	0.01, 0.003
Follow-up data
Follow-up duration (years)	5.07 ± 1.57	5.39 ± 1.58	0.55	5.71 ± 1.53	0.32, 0.71
EDSS remission	1.79 ± 1.01	2.40 ± 0.93	0.01	1.31 ± 0.25	0.30, 0.003
EDSS final	2.02 ± 1.39	4.18 ± 1.87	0.001	1.12 ± 0.23	0.01, 0.001
IFNβ duration (years)	4.01 ± 1.55	2.91 ± 1.68	0.05	NA
ARR under IFNβ	0.18 ± 0.27	1.42 ± 0.75	<0.0001	(0.03 ± 0.09)§
Relapse free (%)	58.82%	0%	<0.0001	87.5%	0.003, <0.0001
EDSS progression-free (%)	94.11%	33.33%	0.01	100%	0.60, 0.001

Data are given as mean ± SD; ARR: annualized relapse rate; GR: good response; PR: poor response, noRx: no treatment; NA: not applicable; NS: not significant (∗chi-square test); ^§corresponds to ARR for the entire follow-up period under noRx; numbers in bold denote statistical significance.